FDA's new expedited drug program raises legal questions and concerns - PBS

The FDA's new expedited drug program has raised legal questions and concerns among major drugmakers, who are hesitant to utilize the fast-track program. Reports indicate that some drugmakers are quietly worried about the legal risks associated with the speedy review process. The FDA chief's efforts to accelerate drug reviews are facing challenges, as highlighted by various sources.